Peregrine Pharmaceuticals’ stock had a rough September. Should investors take advantage of this pullback to add this speculative biopharma to their portfolios?
Peregrine Pharmaceuticals’ stock had a rough September. Should investors take advantage of this pullback to add this speculative biopharma to their portfolios?